Of note, PTPRG mRNA levels remain unchanged in tyrosine kinase inhibitors (TKI) non-responder patients, confirming that downregulation selectively occurs in primary CML cells. The gene discussed is PTPRG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.